Evercore ISI Group Downgrades Crinetics Pharmaceuticals to In-Line, Lowers Price Target to $85

Benzinga Newsdesk www.benzinga.com Negative 92.1%

Neg 92.1% Neu 0% Pos 0%

Evercore ISI Group analyst Gavin Clark-Gartner downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Outperform to In-Line and lowers the price target from $88 to $85.